Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Opgen Inc (OPGN)

Opgen Inc (OPGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 12,533
  • Shares Outstanding, K 8,356
  • Annual Sales, $ 3,420 K
  • Annual Income, $ -32,670 K
  • EBIT $ -9 M
  • EBITDA $ -7 M
  • 60-Month Beta -0.59
  • Price/Sales 4.42
  • Price/Cash Flow N/A
  • Price/Book 5.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.57
  • Most Recent Earnings $1.35 on 11/15/24
  • Next Earnings Date 11/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +7.14%
on 11/13/24
2.0000 -25.00%
on 11/15/24
-0.2100 (-12.28%)
since 10/22/24
3-Month
1.4000 +7.14%
on 11/13/24
2.4800 -39.52%
on 08/26/24
-0.4600 (-23.47%)
since 08/22/24
52-Week
1.4000 +7.14%
on 11/13/24
9.9000 -84.85%
on 03/26/24
-2.6570 (-63.92%)
since 11/22/23

Most Recent Stories

More News
Navigating the Roller Coaster of Recent Penny Stock Surges

Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.

SECO : 0.4049 (+5.17%)
OPGN : 1.5000 (-17.13%)
TPST : 0.9055 (+1.33%)
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI

OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics

OPGN : 1.5000 (-17.13%)
OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a...

OPGN : 1.5000 (-17.13%)
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven

Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility...

OPGN : 1.5000 (-17.13%)
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

Preliminary Total Revenue for Q2 2022 was approximately $1.0 millionCash as of June 30, 2022 was approximately $16.6 millionFirst commercial customer...

OPGN : 1.5000 (-17.13%)
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients

Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of...

OPGN : 1.5000 (-17.13%)
OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel

Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for...

OPGN : 1.5000 (-17.13%)
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar

Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term...

OPGN : 1.5000 (-17.13%)
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic...

OPGN : 1.5000 (-17.13%)
OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12,...

OPGN : 1.5000 (-17.13%)

Business Summary

OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 1.8333
2nd Resistance Point 1.7667
1st Resistance Point 1.6333
Last Price 1.5000
1st Support Level 1.4333
2nd Support Level 1.3667
3rd Support Level 1.2333

See More

52-Week High 9.9000
Fibonacci 61.8% 6.6530
Fibonacci 50% 5.6500
Fibonacci 38.2% 4.6470
Last Price 1.5000
52-Week Low 1.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar